- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 17.07. | enGene Appoints Michael Heffernan As Board Chairman Ahead Of Planned BLA Filing For Bladder Cancer Therapy | 2 | pulse2.com | ||
| 16.07. | enGene appoints Michael Heffernan as board chairman | 1 | Investing.com | ||
| 16.07. | enGene: Michael Heffernan übernimmt Vorsitz des Verwaltungsrats | 1 | Investing.com Deutsch | ||
| 16.07. | enGene Therapeutics Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| ENGENE THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 18.06. | Morgan Stanley cuts Engene stock rating on reduced sales outlook | 2 | Investing.com | ||
| 18.06. | Engene: Morgan Stanley senkt Rating wegen schwächerer Umsatzaussichten | 2 | Investing.com Deutsch | ||
| 16.06. | Neumora depression drug fails; EnGene to cut 50% of staff | 4 | BioPharma Dive | ||
| 16.06. | H.C. Wainwright cuts Engene stock price target on clinical setbacks | 1 | Investing.com | ||
| 15.06. | enGene Holdings GAAP EPS of $0.43 | 1 | Seeking Alpha | ||
| 15.06. | enGene Therapeutics Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 10.06. | enGene Therapeutics Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 08.05. | Analysts cut enGene cancer sales forecast after updated data widen gap to J&J | 13 | FierceBiotech | ||
| 08.05. | Citizens downgrades Engene Holdings stock rating on weaker trial data | 2 | Investing.com | ||
| 08.05. | Citizens stuft Engene Holdings-Aktie nach schwachen Studiendaten ab | 19 | Investing.com Deutsch | ||
| 08.05. | Piper Sandler cuts Engene Holdings stock rating on trial concerns | 1 | Investing.com | ||
| 08.05. | Raymond James downgrades Engene Holdings stock rating on trial results | 2 | Investing.com | ||
| 08.05. | Engene Holdings: Raymond James stuft Aktie nach enttäuschenden Studienergebnissen herab | 9 | Investing.com Deutsch | ||
| 08.05. | Piper Sandler stuft Engene Holdings wegen Bedenken bei klinischer Studie ab | 6 | Investing.com Deutsch | ||
| 08.05. | Engene stock rating cut to Perform by Oppenheimer on trial data | 2 | Investing.com | ||
| 08.05. | Guggenheim stuft Engene-Aktie nach schwachen Studiendaten herab | 8 | Investing.com Deutsch |
1 2 3 Weiter >>
44 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 88,50 | +0,34 % | BioNTech Aktie: Im Rausch der Moderna-Euphorie - Doch wie lange hält die Party an? | © Foto: von fernando zhiminaicela auf Pixabay (Symbolbild)Fast 30 Prozent in einer einzigen Woche. Das ist lange her, dass sowas bei BioNTech vorkam. Zuletzt wohl zu Pandemie-Zeiten ging es mal so zur... ► Artikel lesen | |
| AMGEN | 373,70 | +0,13 % | Amgen's Repatha Reduces Risk Of Death In Patients At High Risk For A First Heart Attack Or Stroke | Repatha is the First and Only PCSK9 Inhibitor Shown to Lower the Risk of Dying from All Causes, Including Cardiovascular Events, in High-Risk Primary Prevention... ► Artikel lesen | |
| NOVAVAX | 7,930 | -0,88 % | Novavax announces regulatory approvals for updated COVID shot | ||
| BIOGEN | 189,12 | +0,29 % | Veeva Systems: Veeva Vault CRM Selected by Biogen | Unified commercial platform to help speed the delivery of medicines to patientsPLEASANTON, Calif., Aug. 25, 2026 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced that Biogen has... ► Artikel lesen | |
| PALATIN TECHNOLOGIES | 10,500 | 0,00 % | Wall Street Wire: StreetWatch: A $2.9 Billion Takeover Put a Spotlight on Relentless Hunger. Palatin Technologies Is Developing the Next Generation of the Drug That Seeks to Treat It | Rare-endocrine buyers have paid roughly $2.9 billion and approximately $10.0 billion for acquisitions in this area over the past four months. IMCIVREE, the only approved MC4R agonist for acquired... ► Artikel lesen | |
| CLINUVEL | 4,920 | -7,73 % | Clinuvel Pharmaceuticals Ltd - 6-K, Report of foreign issuer | ||
| VIKING THERAPEUTICS | 27,650 | -0,36 % | Viking Therapeutics Stock Is Down 66% From Its Peak. Here's What Comes Next. | ||
| INTELLIA THERAPEUTICS | 11,100 | -0,18 % | Cathie Wood's ARK buys Intellia stock, sells Roblox | ||
| TEMPUS AI | 54,80 | -0,85 % | Tempus AI (TEM) Jumped on Moderna's Melanoma Win. Did its $1.5B Personalis Acquisition Just Get Validated? | ||
| EDITAS MEDICINE | 2,750 | +0,73 % | Editas Medicine, Inc.: Editas Medicine Announces Second Quarter 2026 Results and Business Updates | EDIT-401 on track for CTN submission this month with data update in Q1 2027 Recently presented pre-clinical data demonstrating ~90% or greater mean reduction in multiple atherogenic lipoproteins,... ► Artikel lesen | |
| BIOCRYST PHARMACEUTICALS | 8,378 | -1,20 % | BioCryst Pharmaceuticals, Inc.: BioCryst Announces Approval of ORLADEYO for Pediatric HAE Patients in Japan | - Expands availability of the first and only oral prophylactic therapy for patients with HAE ages 2 to RESEARCH TRIANGLE PARK, N.C., Aug. 25, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc.... ► Artikel lesen | |
| BIOMARIN PHARMACEUTICAL | 55,46 | -0,29 % | Ascendis Pharma: Ascendis and BioMarin Enter Binding Term Sheet for a Global Settlement and License Agreement Related to YUVIWEL (Navepegritide) | COPENHAGEN, Denmark, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced it has entered into a binding term sheet for a global settlement and license agreement with... ► Artikel lesen | |
| ABIVAX | 96,90 | -0,87 % | Abivax-Aktie: Zulassungsantrag rückt näher - Übernahme auch? | Die Abivax-Aktie steht vor einer entscheidenden Phase: Nach starken Phase-3-Daten, konstruktivem FDA-Feedback und einer prall gefüllten Kasse rückt der geplante Zulassungsantrag für Obefazimod in den... ► Artikel lesen | |
| EXELIXIS | 47,495 | +1,09 % | BMO initiates Exelixis stock at Market Perform, cites patent cliff | ||
| SAREPTA THERAPEUTICS | 17,960 | -0,22 % | Biotech-Player: Zelltherapie als Comeback-Story im Milliardenmarkt. Neue Ideen nach Corona von BioNTech, Qiagen und Biotech AG |
ENGENE THERAPEUTICS INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell -4,29 % bei einem Aktienkurs von 1,474 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ENGENE THERAPEUTICS INC finden Sie auf Wallstreet Online.